PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of frontimmuLink to Publisher's site
 
Front Immunol. 2017; 8: 328.
Published online 2017 March 21. doi:  10.3389/fimmu.2017.00328
PMCID: PMC5359217

Treatment of Pediatric Acute Graft-versus-Host Disease—Lessons from Primary Immunodeficiency?

Abstract

Allogeneic hematopoietic stem cell transplant (HSCT) is used to treat increasing numbers of malignant and non-malignant disorders. Despite significant advances in improved human leukocyte antigens-typing techniques, less toxic conditioning regimens and better supportive care, resulting in improved clinical outcomes, acute graft-versus-host disease (aGvHD) continues to be a major obstacle and, although it principally involves the skin, gastrointestinal tract, and liver, the thymus is also a primary target. An important aim following HSCT is to achieve complete and durable immunoreconstitution with a diverse T-cell receptor (TCR) repertoire to recognize a broad range of pathogens providing adequate long-term adaptive T-lymphocyte immunity, essential to reduce the risk of infection, disease relapse, and secondary malignancies. Reconstitution of adaptive T-lymphocyte immunity is a lengthy and complex process which requires a functioning and structurally intact thymus responsible for the production of new naïve T-lymphocytes with a broad TCR repertoire. Damage to the thymic microenvironment, secondary to aGvHD and the effect of corticosteroid treatment, disturbs normal signaling required for thymocyte development, resulting in impaired T-lymphopoiesis and reduced thymic export. Primary immunodeficiencies, in which failure of central or peripheral tolerance is a major feature, because of intrinsic defects in hematopoietic stem cells leading to abnormal T-lymphocyte development, or defects in thymic stroma, can give insights into critical processes important for recovery from aGvHD. Extracorporeal photopheresis is a potential alternative therapy for aGvHD, which acts in an immunomodulatory fashion, through the generation of regulatory T-lymphocytes (Tregs), alteration of cytokine patterns and modulation of dendritic cells. Promoting normal central and peripheral immune tolerance, with selective downregulation of immune stimulation, could reduce aGvHD, and enable a reduction in other immunosuppression, facilitating thymic recovery, restoration of normal T-lymphocyte ontogeny, and complete immunoreconstitution with improved clinical outcome as the ability to fight infections improves and risk of secondary malignancy or relapse diminishes.

Keywords: acute graft-versus-host disease, extracorporeal photopheresis, thymopoiesis, dendritic cell, tolerogenesis, primary immunodeficiency

Introduction

Allogeneic hematopoietic stem cell transplant (HSCT) is used to treat a wide variety of malignant and non-malignant disorders. Significant improvements in human leukocyte antigens (HLA)-typing techniques, less toxic conditioning regimens and better supportive care, have resulted in improved clinical outcomes, with over 90% survival and cure for some diseases. An important aim following HSCT is to achieve durable immune reconstitution (IR) with a diverse T-cell receptor (TCR) repertoire capable of recognizing a broad range of pathogens providing adequate adaptive T-lymphocyte immunity long term. This is essential to reduce the risk of infection, disease relapse, and secondary malignancies (1). Although rebuilding of the innate immune system occurs relatively quickly, reconstitution of adaptive immunity is more complex (2). Complete and long-lasting IR depends on a functioning and structurally intact thymus responsible for the production of naïve T-lymphocytes with a broad TCR repertoire (3). Acute graft-versus-host disease (aGvHD) remains a major obstacle to allogeneic HSCT and, although it principally involves the skin, gastrointestinal tract, and liver, the thymus is also a primary target. The consequent damage to the thymic microenvironment disturbs normal signaling required for thymocyte development and results in impaired thymopoiesis and reduced thymic export. First-line treatment for aGvHD is corticosteroids which have a range of direct effects on many aspects of immunity including thymic function, often followed by a plethora of other agents that non-selectively target T-lymphocytes, further interfering with normal T-lymphocyte neogenesis and subjecting patients to an increased risk of infection and relapse. Targeted therapy for aGvHD without systemic immunosuppression, and that allows thymic recovery, is needed.

If the stem cell innoculum is replete, then hematopoietic stem cells are infused with other cells including erythrocytes, donor-tolerized mature lymphocytes, as well as hematopoietic stem cell-derived precursors. The donor-derived T-lymphocytes maybe antigen naïve or experienced and are able to interact with tumor or viral antigen. However, antigen-naïve T-lymphocytes, activated in the post-HSCT millieu, may proliferate and directly attack recipient tissue to cause aGvHD. This initial wave of donor-tolerized T-lymphocyte expansion occurs within the first 120 days. Beyond 120 days, a second wave of T-lymphocyte expansion occurs (or, in the case of a T-lymphocyte depleted donor inoculum, the first wave), as donor stem cell-derived T-lymphocytes that have been tolerized in the recipient thymus are exported into the periphery (4).

Many monogenic disorders of immunity have now been described in patients with primary immunodeficiency (PID). Some of these, including the failure to develop central or peripheral tolerance, as well as the codependence of developing thymocytes and developing thymic stromal cells may give insights into the perpetuation of aGvHD in patients who fail first-line treatment with corticosteroids. This article will review the role of alloreactive T-lymphocytes and treatment of aGvHD in causing thymic damage and apply lessons learnt from the study of patients with PID to patients with resistant aGvHD following allogeneic hematopoietic stem cell transplantation.

Thymic Structure and Normal Thymopoiesis

The thymus is the primary lymphoid organ responsible for the continuous and life-long production of a functional pool of T-lymphocytes exhibiting a widely diverse TCR repertoire, capable of reacting with harmful foreign antigens, but that also recognizes and tolerates self-antigens. The thymus is divided into the subscapular region, the cortex, the cortico-medullary junction, and the medulla. The major cellular components of the thymic stroma include epithelial cells, dendritic cells (DCs), reticular fibroblasts, and macrophages together forming a specialized three-dimensional microenvironment critical for the recruitment of T-lymphocyte precursors followed by an orderly sequential process of T-lymphocyte development and maturation (5). Thymic epithelial cells (TECs) are the major component of the thymic stromal scaffold, divided into two main compartments—the cortical (c) and medullary (m) TECs that exhibit distinct functional properties. A complete, undisrupted thymic microenvironment is essential for normal T-lymphocyte development (6). Conversely, normal thymic architectural development is dependent on input from the developing thymocytes, so called “thymic crosstalk” (7).

Because the thymus does not contain hematopoietic stem cells, progenitor cells are recruited from the bone marrow and enter the thymus at the cortico-medullary junction, with P-selectin and platelet P-selectin glycoprotein ligand on the progenitor cells appearing to play an important role in this homing process (8). Commitment to the T-lymphocyte lineage occurs following interaction between Notch-1 receptor and delta-like 4 ligand expressed by the cTECs (9). At this stage, thymocytes express a “triple negative” (TN) phenotype, devoid of CD3, CD4, and CD8 surface markers. Following expansion of the TN cells, controlled by signals such as IL-7 and Fms-like tyrosine kinase 3 ligand, they gain both CD4 and CD8 to acquire a “double positive” (DP) phenotype with a heterodimeric TCRαβ complex (10, 11). TCR diversity is generated by random genetic rearrangements of the TCR loci and is estimated to be in the region of 1020 α–β chain combinations (5). Because these genetic combinations have the potential to generate self-reactive TCRs, which carry the risk of autoimmunity, thymocytes are subjected to a rigorous two-stage selection process to identify and remove these potentially damaging self-reactive T-lymphocytes (12). The first stage (positive selection) takes place in the cortex where DP thymocytes are exposed to a self-peptide/major histocompatibility complex (MHC) complex presented by cTECs. Thymocytes that recognize this complex with intermediate affinity proceed to the next stage of development, ensuring recognition of antigen in association with self-MHC molecules. If the TCR does not recognize the complex or recognizes with high affinity, the T-lymphocyte will undergo apoptosis or “death by neglect.”

Following positive selection, the surviving thymocytes migrate to the medulla, predominantly regulated by chemokine receptor 7 and the corresponding ligands CCL19 and CCL21 expressed by mTECs, and subsequently lose either CD4 or CD8, dependent on which MHC class they associated with during positive selection, to become “single positive” (SP) cells. The second stage of TCR selection, designated negative selection, occurs in the medulla where SP thymocytes are exposed to a self-peptide/MHC complex presented by mTECs and DCs. Medullary TECs possess the unique ability of ectopic expression of a wide range of peripheral tissue-restricted self-antigens (TRAs). This so called “promiscuous gene expression” is partly controlled by the autoimmune regulator (AIRE) transcription factor, as well as the more recently described Fezf2 transcription factor (13), to form a “molecular mirror of peripheral self” (14, 15). TCRs that react with high affinity to the TRA/MHC complexes are deleted as these have the potential to elicit autoimmunity. Re-encounter of peptides present on both cTECs and mTECs, so called “shared peptides,” also leads to thymocyte deletion, a mechanism thought to increase peptide/MHC diversity (16). Negative selection is an indispensable part of central tolerance, a key process that renders T-lymphocytes tolerant of self.

Peripheral Tolerance

The mature surviving thymocytes, termed recent thymic emigrants (RTEs), are exported into the circulation and expand in response to exposure to antigen or homeostatic signals indicating lymphocytopenia (homeostatic peripheral expansion, HPE) (Figure (Figure1).1). To maintain flexibility in diversity, thymic negative selection is qualified, and some self-reactive T-lymphocytes enter the periphery. Other additional mechanisms are therefore in place to counteract this “escape.” One of these is the production of regulatory T-lymphocytes (Tregs) of which there are two types: natural and inducible. Natural Tregs (nTregs) are produced in the thymus, whereas inducible Tregs (iTregs) are transformed from naïve T-lymphocytes in the periphery upon stimulation. Tregs have an essential role in downregulating peripheral immune responses and limiting inflammation that may be harmful to the host but also in the maintenance of self-tolerance (17). Discrimination between inducible and nTregs is essential to understand fully their specific functions in regulating immune homeostasis as well as their role in different disease states. Expression of Helios has been used as a marker of thymic-derived Tregs, although this has been challenged following the demonstration of induction of Helios expression both in vitro and in vivo (18). Forkhead box transcription factor P3 (Foxp3) plays a critical role in Treg differentiation. It is not clear exactly how nTregs are generated in the thymus, although autoreactive T-lymphocytes may convert to Tregs rather than undergo apoptosis. The exact mechanisms by which they exert their regulatory effects are also not certain. Proposed mechanisms of Tregs include suppression of T-lymphocyte proliferation, alteration of cytokine production and of CD8+, DC, B-lymphocyte, and NK activity. IL-10 and TGFβ are considered to be the central inhibitory cytokines involved in the mechanism of Treg-mediated immunosuppression, but also play a role in the generation of iTregs (19).

Figure 1
Normal thymopoiesis.

Markers of Thymic Output

The peripheral naïve T-lymphocyte pool is maintained by a combination of proliferation of the circulating naïve CD4+ T-lymphocytes and export of naïve T-lymphocytes from the thymus, balanced with apoptosis or differentiation into effector or memory T-lymphocytes. The size of the T-lymphocyte pool is predominantly determined by HPE, but the production of new T-lymphocytes is essential to maintain a broad TCR repertoire. Measuring thymic output provides an indicator of functional T-lymphocyte immunity, and post-HSCT, it indicates reconstitution of the T-lymphocyte compartment.

T-cell receptor excision circles (TRECs) are circular pieces of DNA produced as a consequence of TCRα and TCRβ chain formation. TCRβ chain formation occurs at the TN stage prior to proliferation and generates Dβ-JβTRECs. The TCRα chain is formed at the DP stage of development and generates sjTRECs. Because sjTRECs do not replicate, sjTREC levels become progressively more dilute with naïve T-lymphocyte proliferation. In the setting of post-HSCT lymphocytopenia, this may potentially result in underestimation of the true sjTREC value and thymic activity. However, using PCR, quantification of sjTREC content in T-lymphocytes provides a practical and accepted measurement of thymic output by calculation of the frequency of sjTRECs in a defined population of mononuclear cells or sorted CD4+ or CD8+ T-lymphocytes (20). A more accurate quantification of thymic output is the sjTREC to Dβ-JβTREC ratio (thymic ratio). This represents intrathymic proliferation that occurs between the TN and DP stages, the main determinant of thymic cellularity, which in turn provides a more accurate estimation of thymic output (21). The thymic ratio has the advantage of not being affected by peripheral T-lymphocyte expansion but use is limited by the fact that it is labor intensive and expensive.

No specific surface markers for RTEs have been identified in humans to date. Naïve T-lymphocyte markers such as CD45RA and CD62L are not always reliable as expansion can occur without loss of these markers (22, 23). In addition, CD45RO+ cells can revert back to a CD45RA phenotype. With advances in immunophenotyping techniques, the expression of CD31 (platelet endothelial cell adhesion molecule-1) on naïve CD45RA+CD4+ T-lymphocytes has been used as a marker for RTEs. CD31+CD4+ T-lymphocytes were found to have a high sjTREC content and numbers declined with age (21, 24). However, despite RTEs containing a high content of CD31+CD4+ T-lymphocytes, CD31+CD4+ T-lymphocytes are not exclusive RTE markers as CD31 is not always lost when naïve T-lymphocyte proliferate and CD31 can also be expressed by other cells including endothelial cells, mast cells, and NK cells (25).

The quality of the T-lymphocyte compartment is best assessed by measuring TCR diversity and T-lymphocyte function. As TCR repertoire diversity is almost completely reflective of the naïve T-lymphocyte compartment, measurement can provide information regarding thymic output (26). A more diverse TCR repertoire is also associated with increased TREC concentrations (3). T-lymphocyte functional tests involve measuring levels of cytokines following T-lymphocyte stimulation or detecting the presence of antigen-specific T-lymphocytes.

Primary Immunodeficiencies that Impair Central or Peripheral Tolerance

The significance of the mechanisms described above in developing and maintaining efficient, self-limited host defense while preserving self-tolerance is confirmed by studying patients with primary immunodeficiencies. The importance of thymocyte–TEC cross talk is demonstrated in patients with so called “leaky” severe combined immunodeficiency (SCID) with hypomorphic genetic defects affecting hematopoietic stem cells which almost completely block development of early T-lymphocyte precursors. While null mutations completely abrogate T-lymphocyte development, hypomorphic mutations permit a few T-lymphocyte clones to develop. However, patients experience severe T-lymphocytopenia, infection susceptibility, and autoimmunity. Histological examination of the thymus of patients with null and hypomorphic SCID mutations demonstrates severe thymic atrophy, with loss of cortico-medullary demarcation. Additionally, there is severe impairment of TEC progenitors to differentiate into cTEC and mTEC, leading to absence, or reduction of AIRE expression and of FOXP3-expressing Tregs (27). Thymic DCs are absent. These features lead to failure of thymic TRA expression and presentation, failure of positive and negative T-lymphocyte selection, and failure of thymic nTreg development, leading to a dysregulated TCR repertoire, thymic egress of autoreactive T-lymphocytes, and autoimmunity.

Patients with complete DiGeorge syndrome have genetically normal hematopoietic stem cells, but failure of the embryonic third pharyngeal pouch to form the thymus anlage leads to athymia (or in partial DiGeorge syndrome, atopic microthymus). Neural crest-derived mesenchymal cells of the embryonic pharyngeal arches generate the thymic connective tissue. Thymic mesenchyme promotes thymic epithelium development and signaling between mesenchyme and epithelium controls initial thymic morphogenesis. Mesenchymal cells regulate proliferation and differentiation of immature TEC. However, as thymic development becomes able to support immature thymocytes, further thymic epithelial differentiation is essentially independent of mesenchymal cells. Patients with complete DiGeorge syndrome have no T-lymphocytes, because of athymia rather than an intrinsic hematopoietic stem cell defect. Serial transplantation of allogeneic thymus tissue demonstrates subsequent development of normal thymic architecture from thymic epithelial progenitors, as thymocyte progenitors populate the substrate (28). Thymic development is incomplete however, and autoimmunity may be a feature in transplanted patients (29, 30).

Mutations in AIRE impair thymic medullary TRA expression, leading to impaired negative selection and subsequent multi-organ autoimmunity. In humans, this manifests as the rare condition autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (15, 31). Similarly, loss of Fezf2 in mouse models leads to autoantibody production and autoimmune disease (13).

Mutations in FOXP3 are the cause of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (32). Patients present, usually in early infancy, with autoimmune cytopenias, severe autoimmune enteritis, and type 1 diabetes mellitus. Affected tissues show a T-lymphocyte infiltrate and patients lack functional regulatory FOXP3+ T-lymphocytes, causing failure of peripheral tolerance (33). A number of other PIDs in which autoimmunity is a significant feature are associated with a reduction in Tregs, including Omenn syndrome (34), DiGeorge syndrome (35), and CTLA-4 deficiency (36, 37).

HSCT and T-Lymphocyte Reconstitution

Chemotherapy and/or radiotherapy conditioning is usually given pre-HSCT to remove malignant cells, prevent graft rejection, and make space in the bone marrow for the incoming graft. Subsequently, there is an “aplastic phase,” with obliteration of innate and adaptive immune responses, subjecting the patient to a period of increased risk of infection until donor stem cells engraft and reconstitution of the immune system ensues (38). Recovery of innate immunity occurs relatively quickly, but reconstitution of the adaptive T- and B-lymphocyte compartment is a more lengthy and complex process (2, 39). Incomplete or delayed IR, particularly of the T-lymphocyte compartment, is associated with increased post-transplant morbidity and mortality (40). Thymic function, and consequently thymic output, is negatively affected by advancing age, cytotoxic conditioning pre-HSCT, and GvHD (41). Potential strategies to boost thymic function and promote faster and complete IR, particularly in older patients who exhibit reduced thymic function inherently due to aging, have garnered much interest to improve patient outcome (42).

Restoration of the T-lymphocyte compartment post-HSCT occurs by two parallel pathways (43). Initially after HSCT, the rise in T-lymphocyte numbers is thymic-independent, with expansion of pre-existing surviving host T-lymphocytes or mature donor T-lymphocytes transferred with the graft. However, TCR diversity is dependent upon the repertoire of the initial T-lymphocyte population and expansion results in skewing of the TCR repertoire with time, as well as gradual depletion of T-lymphocytes. This expansion provides an initial degree of immune protection in the post-transplant period, particularly from the host and donor memory T-lymphocytes against re-infection with specific pathogens such as CMV and EBV (26, 44), but is limited in its diversity and permanency, with prevailing susceptibility to infections (41, 45).

Complete and long-lasting IR following lympho-depletion requires durable de novo regeneration of naïve T-lymphocytes from donor progenitor cells within the thymus, which exhibit a broad TCR repertoire capable of recognizing a wide range of pathogens (the thymic-dependent pathway) (46, 47). This process is dependent on a functioning and structurally intact thymus to export a regular stream of recipient-tolerized donor stem cell-derived naïve T-lymphocytes. Swift rebuilding of a competent normo-cellular T-lymphocyte compartment is an essential prerequisite for a normal life enabling regular development and function.

Graft-versus-Host Disease

Despite advances made in the management of HSCT, GvHD remains a leading cause of morbidity and mortality (48), and limits the success and more widespread application of this therapy. The incidence of grade II–IV aGvHD in children ranges from 28 to 56% (49), depending on the degree of histocompatibility, recipient age, underlying condition, and conditioning regimen used (50). Higher aGvHD grades have consistently been associated with worse transplant-related mortality (TRM) and lower overall survival rates (51).

Acute graft-versus-host disease is mediated by donor-tolerized mature T-lymphocytes that recognize and attack disparate host antigens resulting in a harmful inflammatory response. The most important targets are the HLA, encoded by the MHC located on the short arm of chromosome 6, which play a key role in tissue histocompatability and T-lymphocyte recognition (52). The degree of MHC mismatch between donor and recipient is the most important determinant of GvHD, most importantly at the HLA-A, -B, -C, and DRB1 loci (48). However, even in the setting of a HLA-identical sibling HSCT, an alloreactive response can still occur due to mismatch between minor histocompatibility antigens (53).

Pathophysiology of aGvHD

The Billingham criteria identified three requirements necessary for the development of aGvHD (54):

  • The graft must contain immunocompetent cells.
  • There must be a disparity between host antigens and those in the graft.
  • The host must be unable to launch an immune response against this process.

Elucidation of aGvHD pathophysiology is based on experimental models (55): damage to host tissue by conditioning regimens, underlying disease, and/or infections leads to release of pro-inflammatory cytokines such as IFNγ, TNFα, and IL-1 resulting in an inflammatory environment leading to the activation and maturation of host APCs, and upregulation of adhesion and costimulatory molecules. This cultivates an environment that promotes the recruitment of donor alloreactive T-lymphocytes. Donor T-lymphocytes recognize disparate allo-antigens on activated host APCs and become activated, proliferate, differentiate, produce further inflammatory cytokines, and migrate to target organs directed by chemokines, selectins, and integrins. Effector cells, primarily cytotoxic T-lymphocytes and NK cells, and soluble effectors cause apoptosis of target cells mediated by perforin/granzyme and Fas/Fas ligand pathways (56).

Clinical Features of aGvHD

Historically, aGvHD was defined as occurring within the first 100 days following HSCT, and chronic (c) GvHD as after 100 days. However, with the development of new strategies such as reduced intensive conditioning, this definition is less clear and a more recent reclassification now includes both late aGvHD occurring after 100 days and overlap syndrome with features of both (Table (Table1)1) (57).

Table 1
Classification of GvHD (57).

Acute graft-versus-host disease principally involves the skin, GIT, and liver, with skin manifestations occurring most commonly and usually the earliest following engraftment (48, 55, 58). Patients typically develop a pruritic maculo-papular rash, initially around the neck and shoulders, often involving the palms and soles but sparing the scalp. In severe cases, blistering and ulceration can occur. Gastrointestinal aGvHD usually involves diarrhea but may also manifest as vomiting, nausea, anorexia, abdominal pain, and bleeding. Liver involvement typically manifests as cholestasis due to damage to the bile canaliculi, with elevated alkaline phosphatase and serum bilirubin (Table (Table2)2) (59). aGvHD is staged according to the extent of involvement of the skin, GIT, and liver (Table (Table3)3) (59). Severe GvHD is associated with a poor prognosis with a 5% long-term survival for grade 4 and 25% for grade 3.

Table 2
Acute graft-versus-host disease staging of individual organ involvement (59).
Table 3
Overall acute graft-versus-host disease (aGvHD) grading: modified Glucksberg grade (59).

Effect of aGvHD on Thymic Structure, Function, and the T-Lymphocyte Compartment

Although aGvHD principally involves the skin, GIT, and liver, the thymus is also a primary target, resulting in disruption of the thymic architecture. Thymic aGvHD has been shown to cause loss of demarcation between the cortico-medullary zones, loss of Hassall’s corpuscles, alteration of TEC subpopulations, and depletion of thymocytes (6062). The structural damage to the thymic microenvironment consequently impairs lymphocyte formation and export, reflected by lower TREC levels and a distorted TCR repertoire observed in patients, and occurs independent of age (20, 61, 6365). aGvHD also has detrimental effects on the thymic-independent pathway with reduced expansion of transferred mature donor-tolerized T-lymphocytes possibly due to loss of peripheral T-lymphocyte niches (65). The thymus appears to be particularly sensitive to the effects of GvHD with thymic output being significantly affected even in grade 1 disease (26). Subclinical thymic GvHD may even occur in the absence of overt aGvHD (66) with an underappreciated adverse effect on reconstitution of adaptive immunity, causing ongoing infections and incomplete IR post-HSCT.

Although the precise mechanisms behind how aGvHD causes thymic damage in humans remain incompletely understood, experimental aGvHD models have helped to delineate the cellular and molecular mechanisms underlying thymic injury and effects on T-lymphocyte development (60). TECs act as initiators and targets of thymic aGvHD, capable of directly activating alloreactive donor T-lymphocytes independently of APCs (63). Activation of alloreactive donor T-lymphocytes causes IFNγ secretion and stimulation of a STAT1-induced apoptosis pathway resulting in death of TECs (63). The resulting disruption of normal thymic architecture and organization of the microenvironment interrupts the normal signals required for immature thymocytes, leading to thymic atrophy and reduced thymic export. Murine models show that thymocyte damage occurs at two stages of development primarily resulting in loss of DP thymocytes. The first stage involves failure of normal TN thymocyte proliferation, thus failing to produce sufficient numbers of DP thymocytes (60, 61). The second stage is increased apoptosis of DP thymocytes (61, 67). Both events contribute to the reduction in thymic lymphoid cellularity, consequent thymic atrophy, and reduced thymic export. Patients with aGvHD show a decrease in βTREC and sjTREC levels, suggestive of an interference at an early developmental stage (pre-TN thymocyte proliferation) either involving early thymocyte precursors or bone marrow-derived progenitors (20, 21).

A distorted TCR repertoire is observed in patients with aGvHD (20). Normally, all thymic stromal cells exhibit the same MHC haplotype. Following HSCT with HLA mismatch, the radio/chemoresistant cTECs continue to express recipient MHC while recipient medullary DCs will be replaced by donor medullary DCs expressing donor MHC molecules. This MHC disparity disturbs thymic positive and negative selection impacting on TCR selection, resulting in thymocytes escaping negative selection, increasing the survival of reactive T-lymphocytes (6871). It is interesting to speculate whether donor stem cell-derived T-lymphocytes, inadequately tolerized in the recipient thymus are “allo-reactive” or “auto-reactive.” Murine models demonstrate that damage to mTECs by donor CD8+ T-lymphocytes disrupts normal thymic negative selection with escape of autoreactive CD4+ T-lymphocytes into the circulation (72). Thus, aGvHD is detrimental to quantity and quality of T-lymphocyte recovery. Thymic injury from aGvHD resulting in disruption of the normal negative selection process, and thymic Treg development alters the TCR repertoire and promotes escape of autoreactive cells into the circulation, setting the scene for autoimmunity as seen in cGvHD (72) (Figure (Figure2).2). It is well established that aGvHD predisposes to cGvHD but the mechanistic link between them has been uncertain. Recently, Dertschnig et al. demonstrated that impaired thymic ectopic TRA expression secondary to damaged AIRE-expressing mTECs results in disruption to negative selection permitting de novo production of TRA-specific T-lymphocytes which escape into the periphery. TRAs most affected were those that are expressed in tissues known to be targets in cGvHD thus providing a potential link between allo-immunity to the development of autoimmunity (73, 74).

Figure 2
Effect of acute graft-versus-host disease and corticosteroids on thymic function.

Corticosteroids and Thymic Function

First-line treatment of aGvHD is corticosteroids, which exhibit potent immunosuppressive and anti-inflammatory effects. Although they are effective anti-inflammatory agents, they have significant unwanted effects, including increased risk of cardiovascular disease, osteoporosis, and insulin resistance (7577). Despite their successful application in some patients, a complete response is only witnessed in 25–50% of patients with aGvHD. Short intensive corticosteroid courses in avian models induce thymic involution and cause a profound reduction in naïve T-lymphocyte production, although with complete recovery following cessation of corticosteroid treatment (78). However, the effects of long-term corticosteroid use in human thymus are unknown. Both aGvHD and immunosuppressive treatment of aGvHD concurrently impair thymopoiesis subjecting the patient to increased risk of infection and other complications.

Patients who are refractory to corticosteroid treatment have an unfavorable prognosis with increased TRM (79). While corticosteroid are well established as first-line therapy for aGvHD, there is no established consensus to standard second-line therapy for patients with steroid-refractory disease or steroid-dependency and usually involves intensification of systemic immunosuppression with a broad plethora of different therapeutic agents such as mycophenolate mofetil, anti-TNFα antibodies, or mammalian target of rapamycin inhibitors (80). These agents mainly non-selectively target T-lymphocytes resulting in a general immunosuppressive effect, and also likely negatively affect the graft-versus-tumor effect (49).

The insights gained from studying the effects of abnormal T-lymphocyte and thymic development in patients with primary immunodeficiencies are instructive in considering effective treatment of aGvHD. To restore normal immunity, early neutralization of the donor-tolerized T-lymphocytes is required to interrupt target-organ damage, particularly to the thymus, while restoring normal thymic architecture which will facilitate appropriate tolerization of donor stem cell-derived thymocytes to the recipient, with adequate elimination of cells likely to cause autoimmunity. In view of the effect of corticosteroids on thymic architecture and function, the rapid cessation of corticosteroid therapy while maintaining control of alloreactive T-lymphocytes would be desirable.

Extracorporeal Photopheresis (ECP)

Extracorporeal photopheresis involves the collection of peripheral blood mononuclear cells by apheresis, exposure to the photoactive drug 8-methoxypsoralen (8-MOP), and UVA radiation, followed by re-infusion of the photo-activated cells back into the patient (81). The clinical efficacy, safety, and tolerability of ECP in the treatment of aGvHD in patients have been demonstrated in several studies, which also show the steroid-sparing effect (8285). A systematic analysis of prospective studies examining ECP treatment outcomes in corticosteroids refractory/dependent/intolerant aGvHD in adults and children found an overall response rate of almost 70% in all organs, an encouraging result compared to other second-line treatments used (86). Based on the evidence available, the UK Expert Photopheresis Group guidelines state that ECP should be considered as second-line therapy for patients with aGvHD grades II–IV who are steroid refractory/dependant/intolerant. ECP is given as one cycle weekly (two consecutive days) and is recommended for a minimum of 8 weeks (87). Adverse effects of ECP treatment are minimal and predominantly related to central venous access. The mechanistic actions of ECP have not been fully elucidated but likely immune-modulate adaptive and innate immunity, predominantly acting through DCs and Tregs (88, 89).

Exposure to 8-MOP/UVA results in the formation of covalent bonds with pyrimidine bases and subsequent cross-linking of DNA, inducing apoptosis of the exposed cells, with activated T-lymphocytes preferentially affected (81, 90, 91). Apoptosis occurs several hours after ECP and peaks on day 3 (92), possibly due to increased Fas-mediated pro-apoptotic signaling (93). However, as only 5–10% of lymphocytes are exposed during the procedure, an insufficient number to entirely account for the effects of ECP, and considering also that the majority of activated T-lymphocytes reside in the tissues rather than the blood, it is speculated that the ECP-exposed cells have indirect immune-modulatory actions on other non-exposed immune-competent cells.

Following ECP, phagocytosis of the apoptotic cell fragments leads to an immune response directed against alloreactive donor T-lymphocytes.

Monocytes undergo apoptosis more slowly than lymphocytes following ECP (94). ECP promotes differentiation of exposed monocytes to DCs (95), stimulated by the physiological interaction of monocytes with adherent platelets during passage through the ECP chamber (95, 96). Although by day 6 post-ECP 80% of monocytes are apoptotic, functional abilities such as T-lymphocyte stimulation, differentiation into DCs, and endocytosis are preserved, despite impairment of migratory capacities (97). As the majority of DCs typically reside in the tissues, this differentiation of monocytes introduces a much larger number of DCs into the circulation than is normally seen, thus increasing the antigen-presenting capacity. Following ECP, apoptotic cells are localized primarily in the liver and spleen, regions rich with DCs, which ingest the apoptotic alloreactive peptide fragments (98). In aGvHD, phagocytosis of ECP-exposed apoptotic cells results in DCs acquiring an immature tolerogenic state, characterized by downregulation of maturation markers and costimulatory molecules such CD40, CD80, CD83, and CD86 and increased secretion of anti-inflammatory cytokines such as TGFβ and IL-10, resulting in enhanced phagocytic activity but a reduced ability to stimulate an effector T-lymphocyte immune response (91, 99102). IL-10 is a key player in immune downregulation and induction of tolerance, specifically by preventing DC maturation and generating Tregs (91). Monocyte-derived immature DCs also show upregulated expression of the glucocorticoid-induced leucine zipper gene, a marker of tolerogenic DCs, following ECP exposure (103). Upon interaction with T-lymphocytes, tolerogenic DCs can induce anergy or apoptosis, or stimulate the production of Tregs. However, these DCs are not confined to this immature state and can respond to inflammatory signals such as lipopolysaccharide resulting in full maturation (91).

Tregs and ECP

The generation of Tregs is an important immunomodulatory action of ECP. In aGvHD murine models, ECP-treated splenocytes improved aGvHD and IR by reducing the number of non-exposed CD8+ effector lymphocytes, suppressing allogeneic T-lymphocyte proliferation and increasing the number of Tregs (104).

Ten patients with acute and chronic GvHD showed a significant increase in Tregs following ECP, which was accompanied by increased glucocorticoid-induced tumor necrosis factor receptor-related protein expression (105). A larger study involving 27 patients with acute and chronic GvHD showed a significant increase in Treg numbers in those who responded to ECP treatment (106).

Conclusion

In approaching treatment of aGvHD, tipping the balance toward immune tolerance rather than immune suppression and reducing thymic aGvHD, as well as decreasing the burden of immunosuppressive medications, could conceivably allow regeneration of thymic function, as suggested in preliminary evidence by Beattie et al. (107). In this case report of a single patient with aGvHD, there was a temporal association of the commencement of ECP and reduction in corticosteroid dose with a rise in thymic export and Tregs. Further studies are required to substantiate this observation, but if confirmed, ECP would seem an attractive treatment option for aGvHD, given the lack of global immunosuppression with preservation of adaptive immune responses to novel and recall antigens.

Author Contributions

AG conceived the review. AF and AG wrote the review.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding

AF is funded by the Bubble Foundation UK.

References

1. Small TN, Papadopoulos EB, Boulad F, Black P, Castro-Malaspina H, Childs BH, et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood (1999) 93(2):467–80. [PubMed]
2. Storek J, Geddes M, Khan F, Huard B, Helg C, Chalandon Y, et al. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol (2008) 30(4):425–37.10.1007/s00281-008-0132-5 [PubMed] [Cross Ref]
3. Douek DC, Vescio RA, Betts MR, Brenchley JM, Hill BJ, Zhang L, et al. Assessment of thymic output in adults after hematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet (2000) 355(9218):1875–81.10.1016/S0140-6736(00)02293-5 [PubMed] [Cross Ref]
4. Muller SM, Kohn T, Schulz AS, Debatin KM, Friedrich W.. Similar pattern of thymic-dependent T-cell reconstitution in infants with severe combined immunodeficiency after human leukocyte antigen (HLA)-identical and HLA-nonidentical stem cell transplantation. Blood (2000) 96(13):4344–9. [PubMed]
5. Hollander GA, Peterson P.. Learning to be tolerant: how T cells keep out of trouble. J Intern Med (2009) 265(5):541–61.10.1111/j.1365-2796.2009.02093.x [PubMed] [Cross Ref]
6. Holländer GA, Wang B, Nichogiannopoulou A, Platenburg PP, van Ewijk W, Burakoff SJ, et al. Developmental control point in induction of thymic cortex regulated by a subpopulation of prothymocytes. Nature (1995) 373(6512):350–3.10.1038/373350a0 [PubMed] [Cross Ref]
7. van Ewijk W, Shores EW, Singer A.. Crosstalk in the mouse thymus. Immunol Today (1994) 15(5):214–7.10.1016/0167-5699(94)90246-1 [PubMed] [Cross Ref]
8. Rossi FM, Corbel SY, Merzaban JS, Carlow DA, Gossens K, Duenas J, et al. Recruitment of adult thymic progenitors is regulated by P-selectin and its ligand PSGL-1. Nat Immunol (2005) 6(6):626–34.10.1038/ni1203 [PubMed] [Cross Ref]
9. Schmitt TM, Zuniga-Pflucker JC.. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity (2002) 17(6):749–56.10.1016/S1074-7613(02)00474-0 [PubMed] [Cross Ref]
10. Penit C, Lucas B, Vasseur F.. Cell expansion and growth arrest phases during the transition from precursor (CD4-8-) to immature (CD4+8+) thymocytes in normal and genetically modified mice. J Immunol (1995) 154(10):5103–13. [PubMed]
11. Takahama Y.. Journey through the thymus: stromal guides for T-cell development and selection. Nat Rev Immunol (2006) 6(2):127–35.10.1038/nri1781 [PubMed] [Cross Ref]
12. Gill J, Malin M, Sutherland J, Gray D, Hollander G, Boyd R. Thymic generation and regeneration. Immunol Rev (2003) 195:28–50.10.1034/j.1600-065X.2003.00077.x [PubMed] [Cross Ref]
13. Takaba H, Morishita Y, Tomofuji Y, Danks L, Nitta T, Komatsu N, et al. Fezf2 orchestrates a thymic program of self-antigen expression for immune tolerance. Cell (2015) 163(4):975–87.10.1016/j.cell.2015.10.013 [PubMed] [Cross Ref]
14. Anderson MS, Venanzi ES, Chen Z, Berzins SP, Benoist C, Mathis D.. The cellular mechanism of Aire control of T cell tolerance. Immunity (2005) 23(2):227–39.10.1016/j.immuni.2005.07.005 [PubMed] [Cross Ref]
15. Anderson MS, Su MA.. Aire and T cell development. Curr Opin Immunol (2011) 23(2):198–206.10.1016/j.coi.2010.11.007 [PMC free article] [PubMed] [Cross Ref]
16. Klein L, Hinterberger M, Wirnsberger G, Kyewski B.. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol (2009) 9(12):833–44.10.1038/nri2669 [PubMed] [Cross Ref]
17. Sakaguchi S.. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 6(4):345–52.10.1038/ni1178 [PubMed] [Cross Ref]
18. Gottschalk RA, Corse E, Allison JP.. Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol (2012) 188(3):976–80.10.4049/jimmunol.1102964 [PubMed] [Cross Ref]
19. Vignali DA, Collison LW, Workman CJ.. How regulatory T cells work. Nat Rev Immunol (2008) 8(7):523–32.10.1038/nri2343 [PMC free article] [PubMed] [Cross Ref]
20. Clave E, Busson M, Douay C, Peffault de Latour R, Berrou J, Rabian C, et al. Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. Blood (2009) 113(25):6477–84.10.1182/blood-2008-09-176594 [PubMed] [Cross Ref]
21. Ringhoffer S, Rojewski M, Dohner H, Bunjes D, Ringhoffer M. T-cell reconstitution after allogeneic stem cell transplantation: assessment by measurement of the sjTREC/betaTREC ratio and thymic naive T cells. Haematologica (2013) 98(10):1600–8.10.3324/haematol.2012.072264 [PubMed] [Cross Ref]
22. Haynes BF, Markert ML, Sempowski GD, Patel DD, Hale LP.. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu Rev Immunol (2000) 18:529–60.10.1146/annurev.immunol.18.1.529 [PubMed] [Cross Ref]
23. Bains I, Antia R, Callard R, Yates AJ.. Quantifying the development of the peripheral naive CD4+ T-cell pool in humans. Blood (2009) 113(22):5480–7.10.1182/blood-2008-10-184184 [PubMed] [Cross Ref]
24. Junge S, Kloeckener-Gruissem B, Zufferey R, Keisker A, Salgo B, Fauchere JC, et al. Correlation between recent thymic emigrants and CD31+ (PECAM-1) CD4+ T cells in normal individuals during aging and in lymphopenic children. Eur J Immunol (2007) 37(11):3270–80.10.1002/eji.200636976 [PubMed] [Cross Ref]
25. Kohler S, Thiel A.. Life after the thymus: CD31+ and CD31- human naive CD4+ T-cell subsets. Blood (2009) 113(4):769–74.10.1182/blood-2008-02-139154 [PubMed] [Cross Ref]
26. Toubert A, Glauzy S, Douay C, Clave E.. Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: never say never again. Tissue Antigens (2012) 79(2):83–9.10.1111/j.1399-0039.2011.01820.x [PubMed] [Cross Ref]
27. Poliani PL, Facchetti F, Ravanini M, Gennery AR, Villa A, Roifman CM, et al. Early defects in human T-cell development severely affect distribution and maturation of thymic stromal cells: possible implications for the pathophysiology of Omenn syndrome. Blood (2009) 114(1):105–8.10.1182/blood-2009-03-211029 [PubMed] [Cross Ref]
28. Li B, Li J, Devlin BH, Markert ML.. Thymic microenvironment reconstitution after postnatal human thymus transplantation. Clin Immunol (2011) 140(3):244–59.10.1016/j.clim.2011.08.011 [PMC free article] [PubMed] [Cross Ref]
29. Markert ML, Devlin BH, Alexieff MJ, Li J, McCarthy EA, Gupton SE, et al. Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood (2007) 109(10):4539–47.10.1182/blood-2006-10-048652 [PubMed] [Cross Ref]
30. Markert ML, Devlin BH, Chinn IK, McCarthy EA, Li YJ.. Factors affecting success of thymus transplantation for complete DiGeorge anomaly. Am J Transplant (2008) 8(8):1729–36.10.1111/j.1600-6143.2008.02301.x [PMC free article] [PubMed] [Cross Ref]
31. Ferre EM, Rose SR, Rosenzweig SD, Burbelo PD, Romito KR, Niemela JE, et al. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight (2016) 1(13):e88782.10.1172/jci.insight.88782 [PMC free article] [PubMed] [Cross Ref]
32. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet (2001) 27(1):20–1.10.1038/83713 [PubMed] [Cross Ref]
33. Barzaghi F, Passerini L, Bacchetta R.. Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Front Immunol (2012) 3:211.10.3389/fimmu.2012.00211 [PMC free article] [PubMed] [Cross Ref]
34. Cassani B, Poliani PL, Moratto D, Sobacchi C, Marrella V, Imperatori L, et al. Defect of regulatory T cells in patients with Omenn syndrome. J Allergy Clin Immunol (2010) 125(1):209–16.10.1016/j.jaci.2009.10.023 [PubMed] [Cross Ref]
35. McLean-Tooke A, Barge D, Spickett GP, Gennery AR.. Immunologic defects in 22q11.2 deletion syndrome. J Allergy Clin Immunol (2008) 122(2):.e361–4.10.1016/j.jaci.2008.03.033 [PubMed] [Cross Ref]
36. Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med (2014) 20(12):1410–6.10.1038/nm.3746 [PMC free article] [PubMed] [Cross Ref]
37. Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science (2014) 345(6204):1623–7.10.1126/science.1255904 [PMC free article] [PubMed] [Cross Ref]
38. Loren AW, Porter DL, Stadtmauer EA, Tsai DE.. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant (2003) 31(3):145–55.10.1038/sj.bmt.1703806 [PubMed] [Cross Ref]
39. Lum LG.. The kinetics of immune reconstitution after human marrow transplantation. Blood (1987) 69(2):369–80. [PubMed]
40. Bosch M, Khan FM, Storek J.. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol (2012) 19(4):324–35.10.1097/MOH.0b013e328353bc7d [PubMed] [Cross Ref]
41. Krenger W, Blazar BR, Hollander GA.. Thymic T-cell development in allogeneic stem cell transplantation. Blood (2011) 117(25):6768–76.10.1182/blood-2011-02-334623 [PubMed] [Cross Ref]
42. Velardi E, Dudakov JA, van den Brink MRM.. Clinical strategies to enhance thymic recovery after allogeneic hematopoietic stem cell transplantation. Immunol Lett (2013) 155(1–2):31–5.10.1016/j.imlet.2013.09.016 [PMC free article] [PubMed] [Cross Ref]
43. Mackall CL, Hakim FT, Gress RE.. Restoration of T-cell homeostasis after T-cell depletion. Semin Immunol (1997) 9(6):339–46.10.1006/smim.1997.0091 [PubMed] [Cross Ref]
44. Chalandon Y, Degermann S, Villard J, Arlettaz L, Kaiser L, Vischer S, et al. Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications. Blood (2006) 107(1):389–96.10.1182/blood-2005-07-2746 [PubMed] [Cross Ref]
45. Storek J, Gooley T, Witherspoon RP, Sullivan KM, Storb R.. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol (1997) 54(2):131–8.10.1002/(SICI)1096-8652(199702)54:2<131::AID-AJH6>3.0.CO;2-Y [PubMed] [Cross Ref]
46. Dumont-Girard F, Roux E, van Lier RA, Hale G, Helg C, Chapuis B, et al. Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants. Blood (1998) 92(11):4464–71. [PubMed]
47. Hakim FT, Memon SA, Cepeda R, Jones EC, Chow CK, Kasten-Sportes C, et al. Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest (2005) 115(4):930–9.10.1172/JCI200522492 [PubMed] [Cross Ref]
48. Sung AD, Chao NJ.. Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. Stem Cells Transl Med (2013) 2(1):25–32.10.5966/sctm.2012-0115 [PMC free article] [PubMed] [Cross Ref]
49. Rutella S, Valentini CG, Ceccarelli S, Romano MT, Brescia LP, Milano GM, et al. Extracorporeal photopheresis for paediatric patients experiencing graft-versus-host disease (GvHD). Transfus Apher Sci (2014) 50(3):340–8.10.1016/j.transci.2014.04.004 [PubMed] [Cross Ref]
50. Hart JW, Shiue LH, Shpall EJ, Alousi AM.. Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion. Ther Adv Hematol (2013) 4(5):320–34.10.1177/2040620713490316 [PMC free article] [PubMed] [Cross Ref]
51. Das-Gupta E, Dignan F, Shaw B, Raj K, Malladi R, Gennery A, et al. Extracorporeal photopheresis for treatment of adults and children with acute GvHD: UK consensus statement and review of published literature. Bone Marrow Transplant (2014) 49(10):1251–8.10.1038/bmt.2014.106 [PubMed] [Cross Ref]
52. Ball LM, Egeler RM, EBMT Paediatric Working Party . Acute GvHD: pathogenesis and classification. Bone Marrow Transplant (2008) 41(Suppl 2):S58–64.10.1038/bmt.2008.56 [PubMed] [Cross Ref]
53. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med (1996) 334(5):281–5.10.1056/NEJM199602013340501 [PubMed] [Cross Ref]
54. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect (1966) 62:21–78. [PubMed]
55. Ferrara JL, Levine JE, Reddy P, Holler E.. Graft-versus-host disease. Lancet (2009) 373(9674):1550–61.10.1016/S0140-6736(09)60237-3 [PMC free article] [PubMed] [Cross Ref]
56. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J.. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med (1996) 183(2):657–61.10.1084/jem.183.2.657 [PMC free article] [PubMed] [Cross Ref]
57. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 11(12):945–56.10.1016/j.bbmt.2005.09.004 [PubMed] [Cross Ref]
58. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood (1990) 76(8):1464–72. [PubMed]
59. Carpenter PA, Macmillan ML.. Management of acute graft-versus-host disease in children. Pediatr Clin North Am (2010) 57(1):273–95.10.1016/j.pcl.2009.11.007 [PMC free article] [PubMed] [Cross Ref]
60. Krenger W, Rossi S, Piali L, Hollander GA.. Thymic atrophy in murine acute graft-versus-host disease is effected by impaired cell cycle progression of host pro-T and pre-T cells. Blood (2000) 96(1):347–54. [PubMed]
61. Krenger W, Hollander GA.. The immunopathology of thymic GvHD. Semin Immunopathol (2008) 30(4):439–56.10.1007/s00281-008-0131-6 [PubMed] [Cross Ref]
62. Krenger W, Hollander GA.. The role of the thymus in allogeneic hematopoietic stem cell transplantation. Swiss Med Wkly (2010) 140:w13051.10.4414/smw.2010.13051 [PubMed] [Cross Ref]
63. Hauri-Hohl MM, Keller MP, Gill J, Hafen K, Pachlatko E, Boulay T, et al. Donor T-cell alloreactivity against host thymic epithelium limits T-cell development after bone marrow transplantation. Blood (2007) 109(9):4080–8.10.1182/blood-2006-07-034157 [PubMed] [Cross Ref]
64. Krenger W, Schmidlin H, Cavadini G, Hollander GA.. On the relevance of TCR rearrangement circles as molecular markers for thymic output during experimental graft-versus-host disease. J Immunol (2004) 172(12):7359–67.10.4049/jimmunol.172.12.7359 [PubMed] [Cross Ref]
65. Dulude G, Roy DC, Perreault C.. The effect of graft-versus-host disease on T cell production and homeostasis. J Exp Med (1999) 189(8):1329–42.10.1084/jem.189.8.1329 [PMC free article] [PubMed] [Cross Ref]
66. Touzot F, Moshous D, Creidy R, Neven B, Frange P, Cros G, et al. Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCID-X1. Blood (2015) 125(23):3563–9.10.1182/blood-2014-12-616003 [PubMed] [Cross Ref]
67. Krenger W, Rossi S, Hollander GA.. Apoptosis of thymocytes during acute graft-versus-host disease is independent of glucocorticoids. Transplantation (2000) 69(10):2190–3.10.1097/00007890-200005270-00040 [PubMed] [Cross Ref]
68. Hollander GA, Widmer B, Burakoff SJ.. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease. J Immunol (1994) 152(4):1609–17. [PubMed]
69. Tivol E, Komorowski R, Drobyski WR.. Emergent autoimmunity in graft-versus-host disease. Blood (2005) 105(12):4885–91.10.1182/blood-2004-12-4980 [PubMed] [Cross Ref]
70. Teshima T, Reddy P, Liu C, Williams D, Cooke KR, Ferrara JL.. Impaired thymic negative selection causes autoimmune graft-versus-host disease. Blood (2003) 102(2):429–35.10.1182/blood-2003-01-0266 [PubMed] [Cross Ref]
71. Sakoda Y, Hashimoto D, Asakura S, Takeuchi K, Harada M, Tanimoto M, et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood (2007) 109(4):1756–64.10.1182/blood-2006-08-042853 [PubMed] [Cross Ref]
72. Wu T, Young JS, Johnston H, Ni X, Deng R, Racine J, et al. Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells. J Immunol (2013) 191(1):488–99.10.4049/jimmunol.1300657 [PMC free article] [PubMed] [Cross Ref]
73. Dertschnig S, Nusspaumer G, Ivanek R, Hauri-Hohl MM, Hollander GA, Krenger W.. Epithelial cytoprotection sustains ectopic expression of tissue-restricted antigens in the thymus during murine acute GvHD. Blood (2013) 122(5):837–41.10.1182/blood-2012-12-474759 [PubMed] [Cross Ref]
74. Dertschnig S, Hauri-Hohl MM, Vollmer M, Hollander GA, Krenger W.. Impaired thymic expression of tissue-restricted antigens licenses the de novo generation of autoreactive CD4+ T cells in acute GvHD. Blood (2015) 125(17):2720–3.10.1182/blood-2014-08-597245 [PubMed] [Cross Ref]
75. Wei L, MacDonald TM, Walker BR.. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med (2004) 141(10):764–70.10.7326/0003-4819-141-10-200411160-00007 [PubMed] [Cross Ref]
76. de Vries F, Pouwels S, Lammers JW, Leufkens HG, Bracke M, Cooper C, et al. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med (2007) 261(2):170–7.10.1111/j.1365-2796.2006.01754.x [PubMed] [Cross Ref]
77. Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol (2007) 275(1–2):43–61.10.1016/j.mce.2007.05.015 [PubMed] [Cross Ref]
78. Kong FK, Chen CL, Cooper MD.. Reversible disruption of thymic function by steroid treatment. J Immunol (2002) 168(12):6500–5.10.4049/jimmunol.168.12.6500 [PubMed] [Cross Ref]
79. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood (1990) 75(4):1024–30. [PubMed]
80. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2012) 18(8):1150–63.10.1016/j.bbmt.2012.04.005 [PMC free article] [PubMed] [Cross Ref]
81. Knobler R, Barr ML, Couriel DR, Ferrara JL, French LE, Jaksch P, et al. Extracorporeal photopheresis: past, present, and future. J Am Acad Dermatol (2009) 61(4):652–65.10.1016/j.jaad.2009.02.039 [PubMed] [Cross Ref]
82. Gonzalez Vicent M, Ramirez M, Sevilla J, Abad L, Diaz MA.. Analysis of clinical outcome and survival in pediatric patients undergoing extracorporeal photopheresis for the treatment of steroid-refractory GvHD. J Pediatr Hematol Oncol (2010) 32(8):589–93.10.1097/MPH.0b013e3181e7942d [PubMed] [Cross Ref]
83. Perotti C, Del Fante C, Tinelli C, Viarengo G, Scudeller L, Zecca M, et al. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion (2010) 50(6):1359–69.10.1111/j.1537-2995.2009.02577.x [PubMed] [Cross Ref]
84. Messina C, Locatelli F, Lanino E, Uderzo C, Zacchello G, Cesaro S, et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after hematopoietic stem cell transplantation. Br J Haematol (2003) 122(1):118–27.10.1046/j.1365-2141.2003.04401.x [PubMed] [Cross Ref]
85. Berger M, Pessolano R, Albiani R, Asaftei S, Barat V, Carraro F, et al. Extracorporeal photopheresis for steroid resistant graft versus host disease in pediatric patients: a pilot single institution report. J Pediatr Hematol Oncol (2007) 29(10):678–87.10.1097/MPH.0b013e31814d66f5 [PubMed] [Cross Ref]
86. Abu-Dalle I, Reljic T, Nishihori T, Antar A, Bazarbachi A, Djulbegovic B, et al. Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. Biol Blood Marrow Transplant (2014) 20(11):1677–86.10.1016/j.bbmt.2014.05.017 [PubMed] [Cross Ref]
87. Alfred A, Taylor PC, Dignan F, El-Ghariani K, Griffin J, Gennery AR, et al. The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society. Br J Haematol (2017).10.1111/bjh.14537 [PubMed] [Cross Ref]
88. Ratcliffe N, Dunbar NM, Adamski J, Couriel D, Edelson R, Kitko CL, et al. National Institutes of Health state of the science symposium in therapeutic apheresis: scientific opportunities in extracorporeal photopheresis. Transfus Med Rev (2015) 29(1):62–70.10.1016/j.tmrv.2014.09.004 [PubMed] [Cross Ref]
89. Xia CQ, Campbell KA, Clare-Salzler MJ.. Extracorporeal photopheresis-induced immune tolerance: a focus on modulation of antigen-presenting cells and induction of regulatory T cells by apoptotic cells. Curr Opin Organ Transplant (2009) 14(4):338–43.10.1097/MOT.0b013e32832ce943 [PMC free article] [PubMed] [Cross Ref]
90. Marks DI, Rockman SP, Oziemski MA, Fox RM.. Mechanisms of lymphocytotoxicity induced by extracorporeal photochemotherapy for cutaneous T cell lymphoma. J Clin Invest (1990) 86(6):2080–5.10.1172/JCI114945 [PMC free article] [PubMed] [Cross Ref]
91. Spisek R, Gasova Z, Bartunkova J.. Maturation state of dendritic cells during the extracorporeal photopheresis and its relevance for the treatment of chronic graft-versus-host disease. Transfusion (2006) 46(1):55–65.10.1111/j.1537-2995.2005.00670.x [PubMed] [Cross Ref]
92. Heshmati F.. Updating ECP action mechanisms. Transfus Apher Sci (2014) 50(3):330–9.10.1016/j.transci.2014.04.003 [PubMed] [Cross Ref]
93. Tambur AR, Ortegel JW, Morales A, Klingemann H, Gebel HM, Tharp MD. Extracorporeal photopheresis induces lymphocyte but not monocyte apoptosis. Transplant Proc (2000) 32(4):747–8.10.1016/S0041-1345(00)00966-0 [PubMed] [Cross Ref]
94. Maeda A, Schwarz A, Kernebeck K, Gross N, Aragane Y, Peritt D, et al. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J Immunol (2005) 174(10):5968–76.10.4049/jimmunol.174.10.5968 [PubMed] [Cross Ref]
95. Berger C, Hoffmann K, Vasquez JG, Mane S, Lewis J, Filler R, et al. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. Blood (2010) 116(23):4838–47.10.1182/blood-2009-11-256040 [PubMed] [Cross Ref]
96. Edelson RL.. Mechanistic insights into extracorporeal photochemotherapy: efficient induction of monocyte-to-dendritic cell maturation. Transfus Apher Sci (2014) 50(3):322–9.10.1016/j.transci.2013.07.031 [PMC free article] [PubMed] [Cross Ref]
97. Hannani D, Gabert F, Laurin D, Sall M, Molens JP, Hequet O, et al. Photochemotherapy induces the apoptosis of monocytes without impairing their function. Transplantation (2010) 89(5):492–9.10.1097/TP.0b013e3181c6ffd3 [PMC free article] [PubMed] [Cross Ref]
98. Morelli AE, Larregina AT, Shufesky WJ, Zahorchak AF, Logar AJ, Papworth GD, et al. Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood (2003) 101(2):611–20.10.1182/blood-2002-06-1769 [PubMed] [Cross Ref]
99. Capitini CM, Davis JP, Larabee SM, Herby S, Nasholm NM, Fry TJ.. Extracorporeal photopheresis attenuates murine graft-versus-host disease via bone marrow-derived interleukin-10 and preserves responses to dendritic cell vaccination. Biol Blood Marrow Transplant (2011) 17(6):790–9.10.1016/j.bbmt.2010.12.712 [PMC free article] [PubMed] [Cross Ref]
100. Di Renzo M, Sbano P, De Aloe G, Pasqui AL, Rubegni P, Ghezzi A, et al. Extracorporeal photopheresis affects co-stimulatory molecule expression and interleukin-10 production by dendritic cells in graft-versus-host disease patients. Clin Exp Immunol (2008) 151(3):407–13.10.1111/j.1365-2249.2007.03577.x [PubMed] [Cross Ref]
101. Legitimo A, Consolini R, Failli A, Fabiano S, Bencivelli W, Scatena F, et al. In vitro treatment of monocytes with 8-methoxypsolaren and ultraviolet A light induces dendritic cells with a tolerogenic phenotype. Clin Exp Immunol (2007) 148(3):564–72.10.1111/j.1365-2249.2007.03372.x [PubMed] [Cross Ref]
102. Lamioni A, Parisi F, Isacchi G, Giorda E, Di Cesare S, Landolfo A, et al. The immunological effects of extracorporeal photopheresis unraveled: induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation (2005) 79(7):846–50.10.1097/01.TP.0000157278.02848.C7 [PubMed] [Cross Ref]
103. Futterleib JS, Feng H, Tigelaar RE, Choi J, Edelson RL.. Activation of GILZ gene by photoactivated 8-methoxypsoralen: potential role of immunoregulatory dendritic cells in extracorporeal photochemotherapy. Transfus Apher Sci (2014) 50(3):379–87.10.1016/j.transci.2013.10.003 [PMC free article] [PubMed] [Cross Ref]
104. Gatza E, Rogers CE, Clouthier SG, Lowler KP, Tawara I, Liu C, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood (2008) 112(4):1515–21.10.1182/blood-2007-11-125542 [PubMed] [Cross Ref]
105. Biagi E, Di Biaso I, Leoni V, Gaipa G, Rossi V, Bugarin C, et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation (2007) 84(1):31–9.10.1097/01.tp.0000267785.52567.9c [PubMed] [Cross Ref]
106. Di Biaso I, Di Maio L, Bugarin C, Gaipa G, Dander E, Balduzzi A, et al. Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. Transplantation (2009) 87(9):1422–5.10.1097/TP.0b013e3181a27a5d [PubMed] [Cross Ref]
107. Beattie B, Cole D, Nicholson L, Leech S, Taylor A, Robson H, et al. Limited thymic recovery after extracorporeal photopheresis in a low-body-weight patient with acute graft-versus-host disease of the skin. J Allergy Clin Immunol (2015) 137(6):1890.e–3.e.10.1016/j.jaci.2015.10.025 [PubMed] [Cross Ref]

Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA